Nabriva shares tumble as safety worries plague pneumonia drug

(Reuters) – Nabriva Therapeutics Plc’s antibiotic drug to treat a common form of pneumonia met the main goal of a key clinical trial, but concerns over its side effects sent the drug developer’s shares down 13 percent on Monday.


Source: Reuters Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *